← All Inovio Pharmaceuticals, INC filings

Inovio Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
INO
Inovio Pharmaceuticals, INC
10-K: Inovio Pharmaceuticals Faces Going Concern Doubt Amid FDA Scrutiny
Inovio Pharmaceuticals reports a $84.9 million net loss for 2025 and faces substantial doubt about its ability to continue as a going concern, while its lead RRP candidate, INO-3107, encounters FDA questions on accelerated approval eligibility.
NASDAQ
INO
Inovio Pharmaceuticals, INC
10-K: INOVIO Pharmaceuticals Reports 2024 Results, Outlines Path to BLA Submission for INO-3107
INOVIO Pharmaceuticals details its 2024 financial results and provides an update on its clinical programs, including plans for a BLA submission for INO-3107 in mid-2025.
NASDAQ
INO
Inovio Pharmaceuticals, INC
10-K: Inovio Pharmaceuticals Reports Full Year 2023 Results, Focuses on DNA Medicine Pipeline
Inovio Pharmaceuticals' 2023 annual report highlights a strategic shift towards key DNA medicine candidates, particularly INO-3107 for RRP, while managing significant financial losses.